Evommune (NYSE:EVMN) Posts Quarterly Earnings Results, Misses Estimates By $1.49 EPS

Evommune (NYSE:EVMN) announced its quarterly earnings results on Thursday. The company reported ($8.07) earnings per share for the quarter, missing the consensus estimate of ($6.58) by ($1.49), Zacks reports. The company had revenue of $10.00 million for the quarter, compared to the consensus estimate of $10.00 million.

Evommune Price Performance

EVMN stock opened at $18.00 on Friday. Evommune has a fifty-two week low of $16.70 and a fifty-two week high of $24.03.

Analyst Ratings Changes

Several research analysts have recently weighed in on EVMN shares. Zacks Research upgraded Evommune to a “hold” rating in a research note on Tuesday, December 2nd. Wall Street Zen downgraded Evommune from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Leerink Partnrs upgraded shares of Evommune to a “strong-buy” rating in a research note on Monday, December 1st. Cantor Fitzgerald assumed coverage on shares of Evommune in a report on Monday, December 1st. They set an “overweight” rating on the stock. Finally, William Blair assumed coverage on shares of Evommune in a research note on Monday, December 1st. They issued an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $39.33.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions.